Ticker Details
BioMarin Pharmaceutical Inc. Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions.
IPO Date:	August 1, 1999
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$12.31B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.86 | 1.64%
Avg Daily Range (30 D):	$0.96 | 1.64%
Avg Daily Range (90 D):	$0.84 | 1.49%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	1.89M
Avg Daily Volume (90 D):	2.1M

Trade Size
Avg Trade Size (Sh.):	103
Avg Trade Size (Sh.) (30 D):	60
Avg Trade Size (Sh.) (90 D):	60

Institutional Trades
Total Institutional Trades:	24,344
Avg Institutional Trade:	$3.62M
Avg Institutional Trade (30 D):	$4.7M
Avg Institutional Trade (90 D):	$6.26M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	5

Market Closing Trades
Avg Closing Trade:	$11.22M
Avg Closing Trade (30 D):	$21.32M
Avg Closing Trade (90 D):	$27.85M
Avg Closing Volume:	143.74K

News

Feb 12, 2026 @ 5:44 PM BridgeBio Nears 52-Week High On Strong Dwarfism Tr... Source: Vandana Singh

Jan 5, 2026 @ 9:06 AM 10 Magnificent Stocks That Can Make You Richer in ... Source: Sean Williams

Dec 24, 2025 @ 2:14 PM Silver Breaks Above $70, Novo Nordisk Soars 9% On ... Source: Piero Cingari

Dec 23, 2025 @ 6:05 PM What's Going On With BioMarin Stock On Tuesday? Source: Vandana Singh

Nov 3, 2025 @ 6:00 PM Pulmonary Emphysema Market Set to Expand by 2034 w... Source: Delveinsight

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$2.72	$-.16	$1.25
Diluted EPS	$2.67	$-.16	$1.23
Revenue	$3.09B	$776.13M	$825.41M
Gross Profit	$2.52B	$636.05M	$675.32M
Net Income / Loss	$520.42M	$-30.74M	$240.53M
Operating Income / Loss	$615.5M	$-46.69M	$276.89M
Cost of Revenue	$577.87M	$140.09M	$150.09M
Net Cash Flow	$575.9M	$35.55M	$168.08M
PE Ratio	23.45